石四藥集團(02005.HK)2021年純利升28.4%至7.86億港元 整體經營持續穩定向好
格隆匯3月29日丨石四藥集團(02005.HK)公佈2021年度業績,期內集團實現銷售收入53.57億港元,同比增長25.7%;毛利31.70億港元,同比增長17.1%;公司股權持有人應占溢利7.86億港元,同比增長28.4%;每股基本盈利0.2599港元,宣派末期股息每股0.07港元,全年合共派息每股0.12港元,同比增加20%。
針對藥品集採改革深層遞進和新冠肺炎疫情常態化的新形勢,集團在着力推進普通製劑、重點製劑市場開發的同時,結合產業鏈變化需求,堅持整體謀劃、重點突破的原則,加大對重點原料藥和藥包材的產銷提升力度,確保整體經營持續穩定向好。藉助國家集採、省級及區域帶量採購契機,不斷擴大集團產品的市場可及性。
一年來,積極參與國家藥品第四批、第五批集採和過往國採續約,及各省市項目投標、價格聯動、醫院藥品招標活動。鹽酸氨溴索注射液(1ml:7.5mg、2ml:15mg、4ml:30mg)和多索茶礆注射液(10mg:0.1g)兩個品種4種品規在第四批國家藥品集採中中標。氟康唑氯化鈉注射液(100ml:0.2g氟康唑與0.9g氯化鈉)和鹽酸羅呱卡因注射液(10ml:100mg聚丙烯安瓿)兩個品規產品成功中選第五批國家集採。截至目前,集團共有6個品種9個品規產品進入國採,迅速上市實現上量銷售,逐漸成為集團新的效益增長點。
同時,實現了鹽酸溴己新注射液、甲硝唑氯化鈉注射液、乳酸環丙沙星氯化鈉注射液、利奈唑胺葡萄糖注射液、氟康唑氯化鈉注射液、中╱長鏈脂肪乳注射液(C8~24Ve)、硫酸特布他林霧化吸入用溶液、拉考沙胺片、鹽酸右美託咪定注射液等重點品種在20多個省掛網,對穩定市場、提升重點產品和新品種全域開發和市場滲透能力,擴大中標品種銷量和市場覆蓋創造了有利准入條件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.